Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp And Body Psoriasis; Study Met Both Co-Primary Endpoints And All Secondary Endpoints

  Study met both co-primary endpoints and all secondary endpoints At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1%
byBill Haddad
September 26, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

  • Study met both co-primary endpoints and all secondary endpoints
  • At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicle
  • At week eight, 46.5% of individuals treated with roflumilast foam achieved Body-Investigator Global Assessment (B-IGA) Success compared to 20.8% of individuals treated with vehicle
    • Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts